DMRANasdaqPharmaceutical PreparationsFiscal year ends December 31
Damora Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$19.27+0.83 (+4.50%)
Close on Oct 19, 2026
- Market cap
- $1.18B
- P/E (TTM)
- 4.8
- Dividend yield
- 0.00%
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
100.0%
65M of 62M shares
Institutional holders
101
50 new, 13 sold out
Net institutional buying
11M
In Q2 2026
Insider trades, 12 months
1 buys · 4 sales
Net bought $222.22K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Peter Evan Harwin | 8,713,000 | 19.99% | 13D (active) amendment | Feb 9, 2026 |
| Fairmount Healthcare Fund II L.P. | 397,000 | 19.99% | 13D (active) | Nov 10, 2025 |
| Avoro Capital Advisors LLC | 3,783,000 | 6.27% | 13G (passive) | Mar 31, 2026 |
| VHCP Co-Investment Holdings III, LLC | 3,603,595 | 6.00% | 13G (passive) | Feb 9, 2026 |
| BlackRock, Inc. | 3,143,576 | 5.10% | 13G (passive) | Jun 30, 2026 |
| Neil Shahrestani | 285,710 | 21.50% | 13G (passive) | Nov 30, 2025 |
| Abigail P. Johnson | 238,878 | 15.00% | 13G (passive) | Nov 28, 2025 |
| Otto Erik | 2,060,000 | 7.60% | 13G (passive) amendment | Dec 31, 2023 |
| Jain Global LLC | 120,566 | 7.50% | 13G (passive) | Dec 31, 2025 |
| Point72 Asset Management, L.P. | 100,001 | 6.30% | 13G (passive) | Nov 12, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of DMRA | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| FMR LLC | 9,232,979 | 14.96% | $240.15M | +187,498 | 0.01% |
| Fairmount Funds Management LLC | 8,713,000 | 14.11% | $226.63M | – | 14.98% |
| Avoro Capital Advisors LLC | 3,783,000 | 6.13% | $98.40M | – | 0.88% |
| VR Adviser, LLC | 3,603,595 | 5.84% | $93.73M | – | 2.84% |
| BlackRock, Inc. | 3,162,068 | 5.12% | $82.25M | +2,939,631 | 0.00% |
| Fcpm Iii Services B.V. | 2,441,000 | 3.95% | $63.49M | – | 8.46% |
| Ra Capital Management, L.P. | 2,399,702 | 3.89% | $62.42M | +392 | 0.54% |
| Viking Global Investors LP | 2,311,082 | 3.74% | $60.11M | – | 0.17% |
| Jupiter Topco LLC | 2,282,804 | 3.70% | $59.28M | New | 0.02% |
| JPMorgan Chase & Co | 2,058,933 | 3.34% | $49.85M | New | 0.00% |
| Remedium Capital Partners, LLC | 2,045,473 | 3.31% | $53.20M | – | 11.78% |
| Commodore Capital LP | 1,939,000 | 3.14% | $50.43M | – | 3.00% |
| Braidwell LP | 1,620,377 | 2.62% | $42.15M | +725,531 | 1.56% |
| Bellevue Group AG | 1,618,846 | 2.62% | $42.11M | −679,154 | 0.89% |
| State Street Corp | 1,545,500 | 2.50% | $40.20M | +1,361,578 | 0.00% |
| a16z Capital Management, L.L.C. | 1,236,157 | 2.00% | $32.15M | – | 0.23% |
| Balyasny Asset Management L.P. | 1,229,127 | 1.99% | $31.97M | −218,873 | 0.04% |
| Perceptive Advisors LLC | 1,223,000 | 1.98% | $31.81M | – | 0.48% |
| Wellington Management Group Llp | 1,058,000 | 1.71% | $27.52M | – | 0.00% |
| Blackstone Inc. | 1,002,971 | 1.62% | $26.09M | +499,449 | 0.08% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 101 | 65M | 100.0% | 50 / 28 | 9 / 13 | 15M | 4M |
| Q1 2026 | 65 | 56M | 90.9% | 51 / 13 | 0 / 3 | 55M | 0M |
| Q4 2025 | 18 | 1M | 1.8% | 12 / 3 | 3 / 6 | 1M | 0M |
| Q3 2025 | 12 | 0M | 0.3% | 4 / 3 | 3 / 1 | 0M | 0M |
| Q2 2025 | 9 | 0M | 0.2% | 0 / 3 | 4 / 2 | 0M | 0M |
| Q1 2025 | 11 | 0M | 0.2% | 3 / 2 | 1 / 2 | 0M | 0M |
| Q4 2024 | 10 | 0M | 0.2% | 3 / 2 | 2 / 3 | 0M | 0M |
| Q3 2024 | 10 | 0M | 0.2% | 10 / 0 | 0 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of DMRA | Value | % of fund | As of |
|---|---|---|---|---|---|
| Fidelity Growth Company Fund | 1,828,909 | 2.96% | $45.50M | 0.05% | May 31, 2026 |
| iShares Russell 2000 ETF | 1,355,386 | 2.20% | $35.25M | 0.04% | Jun 30, 2026 |
| JPMorgan Small Cap Growth Fund | 741,346 | 1.20% | $19.28M | 0.74% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 714,931 | 1.16% | $18.60M | 0.17% | Jun 30, 2026 |
| Fidelity Growth Company K6 Fund | 535,388 | 0.87% | $13.32M | 0.05% | May 31, 2026 |
| Select Health Care Portfolio | 500,000 | 0.81% | $12.44M | 0.22% | May 31, 2026 |
| Select Biotechnology Portfolio | 454,559 | 0.74% | $11.31M | 0.21% | May 31, 2026 |
| Fidelity Series Growth Company Fund | 452,806 | 0.73% | $11.27M | 0.05% | May 31, 2026 |
| iShares Russell 2000 Growth ETF | 339,291 | 0.55% | $8.82M | 0.06% | Jun 30, 2026 |
| JPMorgan Small Cap Blend Fund | 238,497 | 0.39% | $6.20M | 0.37% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 212,658 | 0.34% | $5.53M | 0.01% | Jun 30, 2026 |
| iShares Russell 2000 Value ETF | 154,350 | 0.25% | $4.01M | 0.03% | Jun 30, 2026 |
| VIP Health Care Portfolio | 118,000 | 0.19% | $3.07M | 0.27% | Jun 30, 2026 |
| VIP Contrafund Portfolio | 105,500 | 0.17% | $2.74M | 0.01% | Jun 30, 2026 |
| Master Small Cap Index Series | 95,134 | 0.15% | $2.47M | 0.04% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Jennifer Jarrett | Director, President and CEO | 512,500 | 0.83% | Sep 28, 2026 |
| Hans T. Schambye | Chief Executive Officer, Director | 4,682 | 0.01% | Jan 6, 2026 |
| Garrett Winslow | General Counsel | 2,289 | 0.00% | Jul 7, 2026 |
| Brian Burkavage | SVP, Finance | – | – | May 8, 2026 |
| Sherwin Sattarzadeh | Chief Operating Officer | 190,376 | 0.31% | Jan 26, 2026 |
| L. Becker Hewes | Chief Medical Officer | 264,629 | 0.43% | Jan 7, 2026 |
| Lori Firmani | Chief Financial Officer | 931 | 0.00% | Jan 6, 2026 |
| Matthew Kronmiller | EVP Strategy and CBO | – | – | Jan 7, 2025 |
| Andrew Cheng | Director | – | – | Aug 13, 2026 |
| Healthcare Fund II L.P. Fairmount | Director, 10% owner | 8,713,000 | 14.11% | Mar 25, 2026 |
| Cameron Turtle | Director | – | – | Mar 25, 2026 |
| Christopher W. Cain | Director | – | – | Mar 25, 2026 |
| Peter Evan Harwin | Director, 10% owner | – | – | Mar 25, 2026 |
| Funds Management LLC Fairmount | Director, 10% owner | – | – | Mar 25, 2026 |
| Julianne Bruno | Director | 137,032 | 0.22% | Mar 25, 2026 |
| Healthcare Co-Invest V. L.P. Fairmount | Director, 10% owner | – | – | Mar 25, 2026 |
| Michael Landsittel | Director | – | – | Mar 25, 2026 |
| David Shapiro | Director | – | – | Jun 20, 2025 |
| Jayson Donald Alexander Dallas | Director | – | – | Jun 20, 2025 |
| Amit Munshi | Director | 4,793 | 0.01% | Jun 20, 2025 |
| Anne Prener | Director | – | – | Jun 20, 2025 |
| Carl Goldfischer | Director | 1,049,055 | 1.70% | Jun 20, 2025 |
| Amy B. Wechsler | Director | – | – | Jun 20, 2025 |
| Tomas Kiselak | 10% owner | – | – | Mar 25, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Jennifer Jarrett Director, President and CEO | Sep 25, 2026 | Buy | +12,500 | $20.23 | $252.88K | 512,500 |
| Garrett Winslow General Counsel | Jul 6, 2026 | Sale | −245 | $29.98 | $7.35K | 2,289 |
| Garrett Winslow General Counsel | Jul 3, 2026 | Option exercise | +680 | – | – | 2,534 |
| Jennifer Jarrett See Remarks, Director | Mar 30, 2026 | Award | +500,000 | – | – | 500,000 |
| Julianne Bruno Director | Feb 9, 2026 | Option exercise | +129,000 | – | – | 137,032 |
| Healthcare Fund II L.P. Fairmount 10% owner | Feb 9, 2026 | Option exercise | +2,904,000 | – | – | 2,904,000 |
| Healthcare Fund II L.P. Fairmount 10% owner | Feb 9, 2026 | Option exercise | +5,809,000 | – | – | 5,809,000 |
| Sherwin Sattarzadeh Chief Operating Officer | Jan 5, 2026 | Award | +190,376 | – | – | 190,376 |
| L. Becker Hewes Chief Medical Officer | Jan 5, 2026 | Award | +264,629 | – | – | 264,629 |
| Hans T. Schambye Chief Executive Officer, Director | Jan 2, 2026 | Sale | −700 | $21.38 | $14.97K | 4,682 |
| Hans T. Schambye Chief Executive Officer, Director | Jan 2, 2026 | Option exercise | +1,360 | – | – | 5,382 |
| Lori Firmani Chief Financial Officer | Jan 2, 2026 | Sale | −135 | $21.41 | $2.89K | 931 |
| Lori Firmani Chief Financial Officer | Jan 2, 2026 | Option exercise | +374 | – | – | 1,066 |
| Garrett Winslow General Counsel | Jan 2, 2026 | Option exercise | +680 | – | – | 2,109 |
| Garrett Winslow General Counsel | Jan 2, 2026 | Sale | −255 | $21.38 | $5.45K | 1,854 |
| Hans T. Schambye Chief Executive Officer, Director | Jul 3, 2025 | Option exercise | +1,360 | – | – | 4,757 |
| Hans T. Schambye Chief Executive Officer, Director | Jul 3, 2025 | Sale | −735 | $3.38 | $2.48K | 4,022 |
| Garrett Winslow General Counsel | Jul 3, 2025 | Sale | −260 | $3.39 | $881 | 1,429 |
| Garrett Winslow General Counsel | Jul 3, 2025 | Option exercise | +680 | – | – | 1,689 |
| Lori Firmani Interim CFO | Jul 3, 2025 | Sale | −147 | $3.39 | $498 | 692 |
| Lori Firmani Interim CFO | Jul 3, 2025 | Option exercise | +374 | – | – | 839 |
| Hans T. Schambye Chief Executive Officer, Director | Jan 3, 2025 | Sale | −1,341 | $5.60 | $7.51K | 3,397 |
| Hans T. Schambye Chief Executive Officer, Director | Jan 3, 2025 | Option exercise | +2,640 | – | – | 4,738 |
| Garrett Winslow General Counsel | Jan 3, 2025 | Sale | −471 | $5.60 | $2.64K | 1,009 |
| Garrett Winslow General Counsel | Jan 3, 2025 | Option exercise | +1,320 | – | – | 1,480 |
| Lori Firmani Interim CFO | Jan 3, 2025 | Sale | −261 | $5.63 | $1.47K | 465 |
| Lori Firmani Interim CFO | Jan 3, 2025 | Option exercise | +726 | – | – | 726 |
| Advisors Israel II Ltd OrbiMed 10% owner | Aug 15, 2023 | Sale | −248,819 | $0.75 | $186.61K | 631,048 |
| Advisors Israel II Ltd OrbiMed 10% owner | Aug 15, 2023 | Sale | −38,327 | $0.75 | $28.75K | 97,204 |
| Advisors Israel II Ltd OrbiMed 10% owner | Aug 15, 2023 | Sale | −535,534 | $0.75 | $401.65K | 1,510,375 |
| Capital GP VII LLC OrbiMed 10% owner | Jul 31, 2023 | Sale | −153,078 | $3.00 | $459.23K | 2,105,909 |
| Capital GP VII LLC OrbiMed 10% owner | Jul 31, 2023 | Sale | −29,700 | $3.00 | $89.10K | 879,867 |
| Capital GP VII LLC OrbiMed 10% owner | Jul 31, 2023 | Sale | −26,622 | $3.00 | $79.87K | 135,531 |
| Capital GP VII LLC OrbiMed 10% owner | Jul 25, 2023 | Sale | −4,700 | $2.92 | $13.72K | 909,567 |
| Capital GP VII LLC OrbiMed 10% owner | Jul 25, 2023 | Sale | −7,800 | $2.92 | $22.78K | 162,153 |
| Capital GP VII LLC OrbiMed 10% owner | Jul 25, 2023 | Sale | −26,700 | $2.92 | $77.96K | 2,258,987 |
| Advisors Israel II Ltd OrbiMed 10% owner | Jul 13, 2023 | Sale | −52,800 | $2.40 | $126.72K | 914,267 |
| Advisors Israel II Ltd OrbiMed 10% owner | Jul 13, 2023 | Sale | −132,100 | $2.40 | $317.04K | 2,285,687 |
| Advisors Israel II Ltd OrbiMed 10% owner | Jul 13, 2023 | Sale | −9,800 | $2.40 | $23.52K | 169,953 |
| Advisors Llc Orbimed 10% owner | Apr 17, 2023 | Sale | −660 | $1.97 | $1.30K | 179,753 |
| Advisors Llc Orbimed 10% owner | Apr 17, 2023 | Sale | −8,878 | $1.97 | $17.49K | 2,417,787 |
| Advisors Llc Orbimed 10% owner | Apr 17, 2023 | Sale | −3,551 | $1.97 | $7.00K | 967,067 |
| Advisors Llc Orbimed 10% owner | Apr 14, 2023 | Sale | −28,110 | $1.86 | $52.28K | 2,426,665 |
| Advisors Llc Orbimed 10% owner | Apr 14, 2023 | Sale | −11,245 | $1.86 | $20.92K | 970,618 |
| Advisors Llc Orbimed 10% owner | Apr 14, 2023 | Sale | −2,091 | $1.86 | $3.89K | 180,413 |
| Advisors Llc Orbimed 10% owner | Apr 13, 2023 | Sale | −703 | $1.82 | $1.28K | 182,504 |
| Advisors Llc Orbimed 10% owner | Apr 13, 2023 | Sale | −3,784 | $1.82 | $6.89K | 981,863 |
| Advisors Llc Orbimed 10% owner | Apr 13, 2023 | Sale | −9,459 | $1.82 | $17.22K | 2,454,775 |
| Advisors Israel II Ltd OrbiMed 10% owner | Apr 12, 2023 | Sale | −641 | $1.81 | $1.16K | 985,647 |
| Advisors Israel II Ltd OrbiMed 10% owner | Apr 12, 2023 | Sale | −119 | $1.81 | $215 | 183,207 |
| Advisors Israel II Ltd OrbiMed 10% owner | Apr 12, 2023 | Sale | −1,603 | $1.81 | $2.90K | 2,464,234 |
| Advisors Israel II Ltd OrbiMed 10% owner | Apr 11, 2023 | Sale | −3,784 | $1.82 | $6.89K | 986,288 |
| Advisors Israel II Ltd OrbiMed 10% owner | Apr 11, 2023 | Sale | −703 | $1.82 | $1.28K | 183,326 |
| Advisors Israel II Ltd OrbiMed 10% owner | Apr 11, 2023 | Sale | −9,459 | $1.82 | $17.22K | 2,465,837 |
| Advisors Israel II Ltd OrbiMed 10% owner | Apr 10, 2023 | Sale | −34,745 | $1.79 | $62.19K | 2,500,582 |
| Advisors Israel II Ltd OrbiMed 10% owner | Apr 10, 2023 | Sale | −13,899 | $1.79 | $24.88K | 1,000,187 |
| Advisors Israel II Ltd OrbiMed 10% owner | Apr 10, 2023 | Sale | −2,584 | $1.79 | $4.63K | 185,910 |
| Genesis GP LLC OrbiMed 10% owner | Apr 6, 2023 | Sale | −487 | $2.00 | $974 | 186,613 |
| Genesis GP LLC OrbiMed 10% owner | Apr 6, 2023 | Sale | −2,620 | $2.00 | $5.24K | 1,003,971 |
| Genesis GP LLC OrbiMed 10% owner | Apr 6, 2023 | Sale | −6,558 | $2.00 | $13.12K | 2,510,041 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Lori Firmani Officer | Aug 6, 2026 | 1,800 | $55.98K | Aug 5, 2026 | Option |
| Lori Firmani Officer | Jun 22, 2026 | 7,615 | $193.14K | Jun 22, 2026 | Option |
| Biotech Growth Trust PLC The Shareholder | Oct 2, 2023 | 57,312 | $41.27K | Oct 2, 2023 | Private Placement |
| OrbiMed Israel Partners II, L.P. Shareholder | Oct 2, 2023 | 244,527 | $176.06K | Oct 2, 2023 | Private placement |
| OrbiMed Private Investments VII, LP Shareholder | Oct 2, 2023 | 585,274 | $421.40K | Oct 2, 2023 | Private placement |
| OrbiMed Genesis Master Fund, L.P. Shareholder | Oct 2, 2023 | 37,675 | $27.13K | Oct 2, 2023 | Private placement |
| OrbiMed Private Investments VII, LP Shareholder | Aug 30, 2023 | 1,222,125 | $708.83K | Aug 30, 2023 | Private placement |
| OrbiMed Genesis Master Fund, L.P. Shareholder | Aug 30, 2023 | 78,659 | $45.62K | Aug 30, 2023 | Private placement |
| OrbiMed Israel Partners II, L.P. Shareholder | Aug 30, 2023 | 510,610 | $296.15K | Aug 30, 2023 | Private placement |
| Biotech Growth Trust PLC The Shareholder | Aug 30, 2023 | 119,679 | $69.41K | Aug 30, 2023 | Private Placement |
| OrbiMed Israel Partners II, L.P. Shareholder | Aug 21, 2023 | 631,048 | $389.36K | Aug 21, 2023 | Private placement |
| Biotech Growth Trust PLC The Shareholder | Aug 21, 2023 | 147,910 | $91.26K | Aug 21, 2023 | Private placement |
| OrbiMed Private Investments VII, LP Shareholder | Aug 21, 2023 | 1,510,375 | $931.90K | Aug 21, 2023 | Private placement |
| OrbiMed Genesis Master Fund, L.P. Shareholder | Aug 21, 2023 | 75,473 | $56.61K | Aug 15, 2023 | Private placement |
| OrbiMed Genesis Master Fund, L.P. Shareholder | Aug 21, 2023 | 97,204 | $59.98K | Aug 21, 2023 | Private placement |